Pfizer says FDA is still reviewing Prevnar 13

[Guest guest]

Must be waiting for more bribe money

Sheri

Pfizer says FDA is still reviewing Prevnar 13

NEW YORK ­ Pfizer Inc. says the Food and Drug Administration is again

extending its review of Prevnar 13, a children’s pneumococcal

vaccine.

The FDA’s decision was due Wednesday, but Pfizer says the agency has not

completed its review. It did not say when the process might be complete.

The FDA was originally scheduled to make a decision by Sept. 30, but

decided to extend that review by three months.

Prevnar 13 is intended to reduce the risk of infection by 13 types of

pneumococcal disease, which can cause ear infections, meningitis,

pneumonia and blood infections. It is a newer version of a vaccine that

has been on the market for nine years, and considered one of the most

important products Pfizer acquired when it bought rival Wyeth for $68

billion this year.

Sheri Nakken, R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start January 6 & 7

http://www.wellwithin1.com/vaccineclass.htm or

http://www.wellwithin1.com/homeo.htm